Welcome to our dedicated page for ABBVIE news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on ABBVIE stock.
AbbVie Inc. (NYSE: ABBV), headquartered in North Chicago, Illinois, is a leading pharmaceutical company ranked 6th on the list of largest biomedical companies by revenue. Known for their commitment to delivering innovative medicines, AbbVie focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. Their portfolio also includes products and services in aesthetics through Allergan Aesthetics, a company they acquired in 2020.
AbbVie’s flagship product, Humira (adalimumab), generated $21 billion in revenue in 2022, accounting for 37% of the company's total revenues. Humira is approved for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. Beyond Humira, AbbVie has developed other notable immunology drugs, including Skyrizi and Rinvoq, which have shown strong market performance.
In the oncology sector, AbbVie markets Imbruvica and Venclexta, which are critical in treating hematological malignancies. The acquisition of Allergan also brought in new products in aesthetics, including Botox, which is not only a cosmetic treatment but also used therapeutically for various conditions.
AbbVie's research and development efforts are robust, with numerous clinical trials ongoing across its therapeutic areas. Recent achievements include positive topline results from the LEVEL UP study, which demonstrated the efficacy of Rinvoq in treating atopic dermatitis. Financially, AbbVie continues to perform well, reporting first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.
Strategic partnerships are also a cornerstone of AbbVie’s growth strategy. Recent collaborations include an agreement with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders and a partnership with Landos Biopharma to enhance their immunology portfolio.
AbbVie remains focused on its mission to address serious health issues and improve patient outcomes globally, leveraging its comprehensive pipeline and innovative solutions in biomedical research.
AbbVie announced it will present findings from the Phase 3 M15-736 trial and data on BOTOX at the 2022 MDS International Congress in Madrid from September 15-18. Key presentations include results on the continuous infusion of ABBV-951 for advanced Parkinson's disease and real-world efficacy of BOTOX for spasticity and cervical dystonia. AbbVie emphasizes its commitment to addressing the needs of patients with movement disorders, reinforcing its leadership in neuroscience.
AbbVie has opened public voting for its 30th annual Cystic Fibrosis (CF) Scholarship program, running until September 28. This year, 40 students living with CF are competing for two $25,000 scholarships based on academic excellence and community involvement. Earlier in 2022, AbbVie awarded $3,000 to 40 CF students, totaling over $3.7 million in scholarships since the program's inception. The winners will be announced in early November, highlighting AbbVie's commitment to supporting the CF community.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the selection of 25 real patients for its new BOTOX® Cosmetic 'See Yourself' campaign after receiving nearly 20,000 submissions. The campaign aims to showcase authentic testimonials and experiences, reflecting the emotional and physical impact of BOTOX® treatments. The latest content includes interviews, treatment diaries, and informative sessions addressing common patient inquiries. BOTOX® Cosmetic remains the leading product in its category, approved by the FDA for treating facial lines.
AbbVie announced 100-week results from KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI (risankizumab) in adults with active psoriatic arthritis. Over 50% of patients achieved a 90% reduction in psoriasis severity (PASI 90), with similar joint symptom improvement (ACR20) as at week 52. The treatment maintained long-term efficacy, with no new safety signals observed. Serious treatment-emergent adverse events were low, with a rate of 7.6 E/100PY in KEEPsAKE 1. These findings were presented at the 31st EADV Congress, highlighting SKYRIZI's potential as a long-term treatment option.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on November 15, 2022, to shareholders of record by October 14, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250%. The company is a member of the S&P Dividend Aristocrats Index, which includes firms that have consistently raised dividends for at least 25 consecutive years.
AbbVie's MEASURE-AD study, spanning three years and 28 countries, highlights the significant clinical, psychosocial, and economic burdens faced by patients with moderate to severe atopic dermatitis, particularly those not on systemic therapy. Results presented at the EADV Congress indicate that these patients experience higher disease severity scores and lower quality of life, emphasizing the need for improved treatment options. The analysis shows that only half of eligible patients receive systemic therapy, revealing potential undertreatment in this population.
AbbVie announced new data from its migraine portfolio at the Migraine Trust International Symposium 2022 in London, from September 8-11. The presentation will include results from the Phase 3 PROGRESS trial for atogepant, aimed at preventing chronic migraine, alongside additional studies on onabotulinumtoxinA and ubrogepant. The company will highlight its commitment to addressing the unmet needs of migraine patients. A medical symposium titled "Evolving Faces of Migraine" will also take place during the event.
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 9:35 a.m. Central time. Key speakers include Rob Michael, Jeff Stewart, and Neil Gallagher. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later in the day.
AbbVie aims to deliver innovative medicines across various fields like immunology, oncology, and neuroscience, enhancing patient care and addressing health challenges.
On August 31, 2022, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), launched the SkinMedica® Firm & Tone Lotion for Body. This innovative product is designed to combat visible signs of body skin aging, such as crepiness and uneven texture. Clinically proven to improve skin firmness and tone, it features a blend of ingredients like Green Microalgae and Shitake Mushroom Extracts. Dermatologists endorse its use both as a standalone product and post body contouring. Priced at $165 USD, it aims to cater to the unique skincare needs of body skin.
FAQ
What is the current stock price of ABBVIE (ABBV)?
What is the market cap of ABBVIE (ABBV)?
What is AbbVie's primary product?
What are the key therapeutic areas AbbVie focuses on?
What significant achievement did AbbVie report in their research efforts?
Who are AbbVie's notable partners?
What are some of AbbVie's key oncology products?
How did AbbVie perform financially in the first quarter of 2024?
What products did AbbVie acquire through Allergan?
What is AbbVie's mission?
What percentage of revenue did Humira contribute in 2022?
Where is AbbVie headquartered?
